Capital Counsel Has Lifted By $328,735 Its Johnson & Johnson Com (JNJ) Holding; Theravance, Inc. (THRX) Had 0 Analysts Last Week

May 27, 2018 - By Louis Casey

Johnson & Johnson (NYSE:JNJ) Logo

Capital Counsel Llc increased Johnson & Johnson Com (JNJ) stake by 0.54% reported in 2017Q4 SEC filing. Capital Counsel Llc acquired 2,365 shares as Johnson & Johnson Com (JNJ)’s stock declined 9.21%. The Capital Counsel Llc holds 442,043 shares with $61.76M value, up from 439,678 last quarter. Johnson & Johnson Com now has $325.80B valuation. The stock increased 0.10% or $0.12 during the last trading session, reaching $121.47. About 4.59M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 1.12% since May 27, 2017 and is uptrending. It has underperformed by 10.43% the S&P500.

Among 3 analysts covering Theravance Biopharma Inc (NASDAQ:THRX), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Theravance Biopharma Inc had 4 analyst reports since September 9, 2015 according to SRatingsIntel. The rating was downgraded by Bank of America on Wednesday, September 9 to “Neutral”. See Theravance, Inc. (NASDAQ:THRX) latest ratings:

It closed at $9.81 lastly. It is down 0.00% since May 27, 2017 and is . It has underperformed by 11.55% the S&P500.

Since February 20, 2018, it had 0 insider purchases, and 3 selling transactions for $385,073 activity. Another trade for 5,378 shares valued at $88,825 was made by dEsparbes Eric on Tuesday, February 20. Another trade for 8,000 shares valued at $132,100 was sold by ABERCROMBIE GEORGE B. $164,148 worth of Theravance, Inc. (NASDAQ:THRX) was sold by Witek Theodore J. Jr. on Tuesday, February 20.

Investors sentiment decreased to 0.04 in Q4 2017. Its down 0.04, from 0.08 in 2017Q3. It fall, as 28 investors sold Theravance, Inc. shares while 0 reduced holdings. 0 funds opened positions while 1 raised stakes. 1.85 million shares or 0.82% more from 1.84 million shares in 2017Q3 were reported. Retail Bank Of New York Mellon Corporation has 850,000 shares. Moreover, Vertex One Asset Management has 0.08% invested in Theravance, Inc. (NASDAQ:THRX) for 500,000 shares. Iron Financial Limited Liability holds 0.35% or 500,000 shares.

Since February 15, 2018, it had 0 buys, and 1 sale for $20.17 million activity. Stoffels Paulus sold 155,342 shares worth $20.17M.

Capital Counsel Llc decreased Roche Hldg Ltd Sponsored Adr (RHHBY) stake by 127,446 shares to 1.36M valued at $43.01 million in 2017Q4. It also reduced Mettler Toledo International C (NYSE:MTD) stake by 2,801 shares and now owns 225,346 shares. Intel Corp Com (NASDAQ:INTC) was reduced too.

Investors sentiment increased to 0.87 in 2017 Q4. Its up 0.04, from 0.83 in 2017Q3. It improved, as 35 investors sold JNJ shares while 884 reduced holdings. 143 funds opened positions while 654 raised stakes. 1.72 billion shares or 0.40% more from 1.71 billion shares in 2017Q3 were reported. Global X Mgmt Communication Ltd has 4,360 shares for 0.01% of their portfolio. Private Capital has 0.32% invested in Johnson & Johnson (NYSE:JNJ). Enterprise Svcs Corporation has 1.02% invested in Johnson & Johnson (NYSE:JNJ). Dynamic Advsr Solutions Ltd Llc reported 0.95% stake. Cv Starr Tru, a New York-based fund reported 40,000 shares. Sterling Cap Mgmt invested in 1.1% or 869,788 shares. Panagora Asset Management reported 0.74% of its portfolio in Johnson & Johnson (NYSE:JNJ). Highlander Capital Management Lc holds 0.81% or 7,930 shares. Ycg Limited Liability Corporation has 0.49% invested in Johnson & Johnson (NYSE:JNJ) for 14,347 shares. Boyd Watterson Asset Management Limited Liability Corporation Oh has 17,450 shares for 1.18% of their portfolio. Fayerweather Charles reported 24,823 shares. Edgewood Mgmt Limited Liability Company accumulated 34,056 shares. Haverford Trust reported 3.08% stake. Huntington National Bank reported 567,945 shares. Nepsis Incorporated has 3.47% invested in Johnson & Johnson (NYSE:JNJ).

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: which released: “Congo begins Ebola vaccinations” on May 21, 2018, also with their article: “Johnson & Johnson: Waiting On The Wave” published on May 11, 2018, published: “Johnson & Johnson (NYSE:JNJ) Heffx Stock Technicals” on May 18, 2018. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: and their article: “Johnson & Johnson Stock Looks Attractive on the Big Dip” published on May 10, 2018 as well as‘s news article titled: “Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV)” with publication date: May 02, 2018.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 11 have Buy rating, 5 Sell and 7 Hold. Therefore 48% are positive. Johnson & Johnson had 101 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Johnson & Johnson (NYSE:JNJ) earned “Outperform” rating by Cowen & Co on Tuesday, August 25. Argus Research upgraded the stock to “Buy” rating in Wednesday, July 20 report. The rating was maintained by BMO Capital Markets with “Buy” on Tuesday, July 18. The stock of Johnson & Johnson (NYSE:JNJ) has “Buy” rating given on Tuesday, October 17 by BMO Capital Markets. Vetr downgraded Johnson & Johnson (NYSE:JNJ) on Monday, August 31 to “Strong-Buy” rating. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by UBS on Wednesday, October 19. The firm has “Buy” rating given on Thursday, August 31 by UBS. The rating was maintained by Leerink Swann with “Buy” on Wednesday, April 18. Citigroup initiated Johnson & Johnson (NYSE:JNJ) on Monday, September 25 with “Hold” rating. The stock has “Buy” rating by RBC Capital Markets on Friday, September 22.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: